Gilead Sciences Completes Acquisition of YM BioSciences

  Gilead Sciences Completes Acquisition of YM BioSciences

Business Wire

FOSTER CITY, Calif. -- February 8, 2013

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has completed its
acquisition of YM BioSciences Inc. (NYSE MKT: YMI, TSX: YM).

On February 8, 2013, a subsidiary of Gilead acquired all of the outstanding
common shares of YM pursuant to the terms of a plan of arrangement. As a
result, YM has become a wholly-owned subsidiary of Gilead and it is
anticipated that the common shares of YM will no longer be listed for trading
on the NYSE MKT LLC or the Toronto Stock Exchange, on or about February 12,
2013. Shareholders of YM on this date will be entitled to receive U.S. $2.95
per common share in cash, and holders of warrants and stock options will be
entitled to receive a cash payment equal to the difference between U.S. $2.95
and the exercise price of such warrant or stock option.

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and
commercializes innovative therapeutics in areas of unmet medical need.
Gilead’s mission is to advance the care of patients suffering from
life-threatening diseases worldwide. Headquartered in Foster City, California,
Gilead has operations in North America, Europe and Asia Pacific.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 that are subject to
risks, uncertainties and other factors, including risks related to the ability
of Gilead to advance YM's product pipeline, including CYT387, and the
possibility of unfavorable results of clinical trials of CYT387. These risks,
uncertainties and other factors could cause actual results to differ
materially from those referred to in the forward-looking statements. The
reader is cautioned not to rely on these forward-looking statements. These and
other risks are described in detail in Gilead’s Quarterly Report on Form 10-Q
for the quarter ended September 30, 2012, as filed with the U.S. Securities
and Exchange Commission. All forward-looking statements are based on
information currently available to Gilead, and Gilead assumes no obligation to
update any such forward-looking statements.

For more information on Gilead Sciences, please visit the company’s website at, follow Gilead on Twitter (@GileadSciences) or call Gilead
             Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.


Gilead Sciences, Inc.
Patrick O’Brien, 650-522-1936 (Investors)
Nathan Kaiser, 650-522-1853 (Media)
Press spacebar to pause and continue. Press esc to stop.